Clearmind Medicine published U.S. Patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines. The applications address potential uses in depression, PTSD, pain and substance use disorders, giving investors a defined expansion of the company’s intellectual-property portfolio while patent outcomes remain uncertain.
Key Highlights
- Clearmind Medicine’s U.S. patent applications were published on September 23, 2026.
- The intellectual-property work is connected to collaboration with NeuroThera Labs Inc..
- Clearmind said its approach is intended to pursue therapeutic effects at lower doses while preserving efficacy.
The company expanded its U.S. intellectual-property position by publishing patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines. The applications address potential therapeutic uses in mental health disorders, pain and substance use disorders.
U.S. Applications Cover Psychedelic Combinations
The proposed combinations include N-acylethanolamines such as palmitoylethanolamide, or PEA. Potential areas identified include depression, post-traumatic stress disorder, pain and substance use disorders. Clearmind (NASDAQ: CMND) said its approach is intended to pursue therapeutic effects at lower doses while preserving efficacy, although it cautioned that a pending application may not result in an issued patent or a form advantageous to the company.
FAQs
Q: When did Clearmind Medicine publish the U.S. patent applications?
A: Clearmind Medicine published the U.S. patent applications on September 23, 2026. The publications cover combinations involving LSD, ketamine and ibogaine.
Q: What compounds are covered by Clearmind Medicine’s patent applications?
A: The applications cover LSD, ketamine and ibogaine combined with N-acylethanolamines, including palmitoylethanolamide, in potential therapeutic programs.
Q: Which conditions could the Clearmind Medicine combinations address?
A: The potential indications include depression, post-traumatic stress disorder, pain and substance use disorders. The company also referenced anxiety and eating disorders for its earlier MDMA combination application.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.